Swedish biotech AnaCardio has raised €62.5 million to take its oral heart failure drug AC01 through Phase 2b, testing whether early improvements in pumping function hold up in a larger patient population.
Tag Archive for: fundraising
London-based Basecamp Research has raised $140 million (€122 million) in an oversubscribed Series C to expand its biological AI models and move a preclinical therapeutics pipeline toward the clinic. Its first focus is in vivo cell therapy.
German biotech ViferaXS has closed a Series A financing of up to €12 million, including grant funding, to advance its peptide-based cancer immunotherapy into a randomized Phase 2 trial in chronic lymphocytic leukemia (CLL).
Dutch biotech Matisse Pharmaceuticals has raised €14 million in a Series A financing to advance isupartob sodium through Phase 2 development in sepsis.
The French hearing-loss biotech has taken the first formal step toward a potential U.S. listing, as it advances its remaining gene therapy program into the clinic.
Hanover-based Allogenetics has raised €3.8 million in a Pre-Series A round to advance ALG-115, an ex vivo gene therapy for donor lungs, through IND-enabling studies and toward a first-in-human trial planned for late 2027 or early 2028.
German biotech Immatics is raising $150 million (€128.6 million) through an underwritten offering to strengthen its balance sheet ahead of a pivotal readout for its lead cancer cell therapy, anzu-cel.
Scottish biotech Mironid has raised $46 million (€40 million) in a Series B financing to advance MR-L45, its small-molecule candidate for autosomal dominant polycystic kidney disease (ADPKD) through clinical development.
Berlin-based Pentixapharm Holding AG has raised about €20.4 million to fund a pivotal Phase 3 trial of its PET diagnostic PentixaFor and advance its CXCR4-targeted theranostics pipeline.
Welsh biotech Draig Therapeutics has raised an oversubscribed $65 million Series B to accelerate its neuropsychiatry pipeline, taking its total funding to $205 million little more than a year after emerging from stealth.